Risperidone-Lurasidone

Risperidone
Type antipsychotic
Group atypical AP
Other use moodstabilizer
links
ATC-code N05AX08
Medscape Risperidone
PubChem 5073
PubMed Risperidone
Drugs.com risperidone
Kompas (Dutch) Risperidone
Wikipedia Risperidone
Lurasidone
Type Antipsychotic
Group Atypical AP
links
Medscape Lurasidone
PubMed Lurasidone
Kompas (Dutch) Lurasidone
Wikipedia Lurasidone

Switch medication from Risperidone to Lurasidone.

Nietinrijdenbord.png Stop Risperidone
  • Day 1-4: approx. 75% of initial dose
  • Day 5-8: approx. 50% of initial dose
  • Day 9-12: approx. 25% of initial dose
  • Day 13: stop
Eenrichtingbord.png Start Lurasidone
  • Day 1-4: approx. 25% of target dose
  • Day 5-8: approx. 50% of target dose
  • Day 9-12: approx. 75% of target dose
  • Day 13: target dose
Infobord.png More information
  • More information on switching to lurasidon: see reference. [4]
    Switchstandaardup en down.jpg
Nietinrijdenbord.png — Risperidone
Eenrichtingbord.png — Lurasidone


  1. ↑ 1.01.1 KNMP; Informatorium Medicamentorum 2015; Monografie "risperidon" (Dutch)
  2. ↑ Woods SW; Chlorpromazine equivalent doses for the newer atypical antipsychotics J Clin Psychiatry 2003;64:663-667
  3. ↑ 3.03.1 The Lundbeck Institute; Psychotropics; Terminal Plasma Half-lives
  4. ↑ McEvoy JP et al. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study.J Clin Psychiatry. 2013 Feb;74(2):170-9.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.